These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9796964)

  • 1. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.
    Synold TW; Newman EM; Carroll M; Muggia FM; Groshen S; Johnson K; Doroshow JH
    Clin Cancer Res; 1998 Oct; 4(10):2349-55. PubMed ID: 9796964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.
    Wedge SR; Laohavinij S; Taylor GA; Boddy A; Calvert AH; Newell DR
    Clin Cancer Res; 1995 Dec; 1(12):1479-86. PubMed ID: 9815947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
    Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
    Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.
    Sessa C; de Jong J; D'Incalci M; Hatty S; Pagani O; Cavalli F
    Clin Cancer Res; 1996 Jul; 2(7):1123-7. PubMed ID: 9816277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
    Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH
    Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid.
    Alati T; Worzalla JF; Shih C; Bewley JR; Lewis S; Moran RG; Grindey GB
    Cancer Res; 1996 May; 56(10):2331-5. PubMed ID: 8625328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol.
    Muggia FM; Synold TW; Newman EM; Jeffers S; Leichman LP; Doroshow JH; Johnson K; Groshen S
    J Natl Cancer Inst; 1996 Oct; 88(20):1495-6. PubMed ID: 8841028
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.
    Rafi I; Taylor GA; Calvete JA; Boddy AV; Balmanno K; Bailey N; Lind M; Calvert AH; Webber S; Jackson RC
    Clin Cancer Res; 1995 Nov; 1(11):1275-84. PubMed ID: 9815922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
    Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet.
    Habeck LL; Chay SH; Pohland RC; Worzalla JF; Shih C; Mendelsohn LG
    Cancer Chemother Pharmacol; 1998; 41(3):201-9. PubMed ID: 9443636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of wheat breakfast rolls fortified with folic acid. The effect on folate status in women during a 3-month intervention.
    Johansson M; Witthöft CM; Bruce A; Jägerstad M
    Eur J Nutr; 2002 Dec; 41(6):279-86. PubMed ID: 12474072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of plasma reduced folates after folic acid administration.
    Priest DG; Schmitz JC; Bunni MA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):38-41. PubMed ID: 10598553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of antitumor antifolates.
    Newell DR
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):74-81. PubMed ID: 10598559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol.
    Mendelsohn LG; Gates SB; Habeck LL; Shackelford KA; Worzalla J; Shih C; Grindey GB
    Adv Enzyme Regul; 1996; 36():365-81. PubMed ID: 8869756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
    Stapleton SL; Reid JM; Thompson PA; Ames MM; McGovern RM; McGuffey L; Nuchtern J; Dauser R; Blaney SM
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):461-6. PubMed ID: 16855840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
    Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
    J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.